Serum levels of IL-17A and cathelicidin antimicrobial peptide LL37 in females with breast cancer
DOI:
https://doi.org/10.13181/mji.oa.257971Keywords:
breast cancer, IL-17A, LL37 protein, metastasisAbstract
BACKGROUND Breast cancer (BC) is a leading cause of morbidity and mortality in women. Interleukin (IL)-17 and the antimicrobial peptide LL37 have been implicated in BC pathogenesis. This study aimed to assess their levels in women with BC and evaluate their correlation with molecular subclasses, clinical, and laboratory parameters.
METHODS This study included 69 BC females and 35 healthy controls. Patients were classified based on metastatic status and molecular indicators. Serum IL-17A and LL37 concentrations were estimated using ELISA and compared across patient subgroups. The area under the curve (AUC) was analyzed to determine cut-off values, sensitivity, and specificity for their diagnostic potential in BC.
RESULTS IL-17A and LL37 levels were notably higher in patients with BC than in controls (p<0.0001). LL37 levels were also higher in the metastatic than in the non-metastatic group and controls. IL-17A levels were considerably higher in patients with metastatic than in controls (p<0.0001), but did not differ significantly between metastatic and non-metastatic patients (p = 0.5573). Regarding diagnostic performance, LL37 showed an AUC of 0.989 (p<0.001) at the best cut-off value of 16.79 ng/ml, LL37 exhibited 95% sensitivity and 94% specificity, indicating diagnostic potential. IL-17A showed an AUC of 0.87 (p<0.001), with a best cut-off value of 15.11 pg/ml, 78.81% sensitivity, and 100% specificity. Both LL37 and IL-17A levels were correlated with each other (r = 0.284, p = 0.018).
CONCLUSIONS Patients with BC had increased serum levels of IL-17A and LL37. Their estimation is important for the follow-up of patients with metastatic.
Downloads
References
Hassan BA, Mohammed AH, Ahmed AA, Al Zobair AA, Wayyes AM, Al-Jawadi HK, et al. Enhancing women's quality of life: exploring the impact of mastectomy with and without breast reconstruction among breast cancer survivors in Iraq. APJCP. 2024;25(3):1097-105. https://doi.org/10.31557/APJCP.2024.25.3.1097
Al-Hasso IK. Assessment of serum soluble toll-like receptor-4 and interleukin-8 as biomarkers in patients with breast cancer. Al-Rafidain J Med Sci. 2024;6(1):167-71. https://doi.org/10.54133/ajms.v6i1.568
Al Obeidy BF, Zobair AA, Jawher NM, Zheng F. Relationship between vitamin D3 level and body mass index in postmenopausal breast cancer patients. Med J Babylon. 2022;19(4):671-5. https://doi.org/10.4103/MJBL.MJBL_207_22
Khudhair JA, Khitam MA, Hasan AH, Nasser LM, Selman KJ, Mohamed MH, et al. Annual Report Iraqi Cancer Registry. Baghdad (Iraq): Republic of Iraq Ministry of Health and Environment Iraqi Cancer Board; 2020.
Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21(6):1462. https://doi.org/10.1038/s41436-019-0459-4
Al-Tae FM, Al-Harbi AA, Turki KW, Sood M. Interleukin -37 in rheumatoid arthritis: correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq. Egypt J Immunol. 2023;30(2):162-73. https://doi.org/10.55133/eji.300215
Welte T, Zhang XH. Interleukin-17 could promote breast cancer progression at several stages of the disease. Mediators Inflamm. 2015;2016:804347. https://doi.org/10.1155/2015/804347
Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, Impellizzieri D, Lacanfora L, et al. Much more than IL-17A: cytokines of the IL-17 family between microbiota and cancer. Front Immunol. 2020;11:565470. https://doi.org/10.3389/fimmu.2020.565470
Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 2013;3:3456. https://doi.org/10.1038/srep03456
Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951-9. https://doi.org/10.1182/blood.V97.12.3951
Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z, et al. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res. 2009;11(1):R6. https://doi.org/10.1186/bcr2221
Yang B, Good D, Mosaiab T, Liu W, Ni G, Kaur J, et al . Significance of LL‐37 on immunomodulation and disease outcome. BioMed Res Int. 2020;2020:8349712. https://doi.org/10.1155/2020/8349712
Pan WL, Wang Y, Hao Y, Wong JH, Chan WC, Wan DC, et al. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864(11):3837-46. https://doi.org/10.1016/j.bbadis.2018.09.008
Speidel J. Detection methods. In: Speidel J, ed. Introduction to Digital Communications. 2nd ed. Cham: Springer; 2021. p31-46. https://doi.org/10.1007/978-3-030-67357-4_3
Allison KH, Hammond ME, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med. 2020;144(5):545-63. https://doi.org/10.5858/arpa.2019-0904-SA
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-46. https://doi.org/10.1093/annonc/mdv221
Park S, Park S, Kim J, Ahn S, Park KH, Lee H. Assessment of Ki-67 for predicting effective prognosis in breast cancer subtypes. Biomed Sci Letters. 2018;24(1):9-14. https://doi.org/10.15616/BSL.2018.24.1.9
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. https://doi.org/10.1093/annonc/mdt303
Al Zobair A, Hayawi MA, Al Obeidy BF. Reliability of CA15-3 tumor marker in monitoring therapeutic response in different molecular subtypes of metastatic breast cancer. MEJC. 2022;13(3):438-48.
Piktel E, Niemirowicz K, Wnorowska U, Wątek M, Wollny T, Głuszek K, et al. The role of cathelicidin LL-37 in cancer development. Arch Immunol Ther Exp (Warsz). 2016;64(1):33-46. https://doi.org/10.1007/s00005-015-0359-5
El-Batal HM, Kamel MM, Moaz I, Gohar NM. Evaluation of interleukin-17 A Levels in patients with breast carcinoma. Egypt J Immunol. 2024;31(1):174-83. https://doi.org/10.55133/eji.310118
Avalos-Navarro G, Muñoz-Valle JF, Daneri-Navarro A, Quintero-Ramos A, Franco-Topete RA, Morán-Mendoza AJ, et al. Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clin Exp Med. 2019;19(3):385-91. https://doi.org/10.1007/s10238-019-00559-6
Popovic LS, Matovina-Brko G, Popovic M, Punie K, Cvetanovic A, Lambertini M. Targeting triple-negative breast cancer: a clinical perspective. Oncol Res. 2023;31(3):221-38. https://doi.org/10.32604/or.2023.028525
Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E, et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 2005;114(5):713-9. https://doi.org/10.1002/ijc.20795
Ayari J, Karrit S, Haj Ammar S, Bouhlel M, Belti M, Zribi A, et al. Prognostic value of circulating cytokines in breast cancer. Cancer Med. 2020;3(1):1-9. https://doi.org/10.46619/Cmj.2020.3-1015
Autenshlyus A, Davletova K, Varaksin N, Marinkin I, Lyakhovich V. Cytokines in various molecular subtypes of breast cancer. Int J Immunopathol Pharmacol. 2021;35:20587384211034089. https://doi.org/10.1177/20587384211034089
Chen J, Shin VY, Ho JCW, Siu MT, Cheuk IW, Kwong A. Functional implications of cathelicidin antimicrobial protein in breast cancer and tumor-associated macrophage microenvironment. Biomolecules. 2020;10(5):688. https://doi.org/10.3390/biom10050688
Liu G, Chen XT, Zhang H, Chen X. Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients. Front Oncol. 2022;12:1019247. https://doi.org/10.3389/fonc.2022.1019247
Hwang YJ, Jung HJ, Kim MJ, Roh NK, Jung JW, Lee YW, et al. Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediators Inflamm. 2014;2014:268257. https://doi.org/10.1155/2014/268257
Altieri A, Lloyd D, Ramotar P, van der Does AM, Hemshekhar M, Mookherjee N. LL-37 modulates IL-17A/F-mediated airway inflammation by selectively suppressing Lipocalin-2. CSHL. 2024:1-41. https://doi.org/10.1101/2024.09.03.610924
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ahmed Abdullah Ahmed Al-Harbi, Asmaa Zaki Shetawi, Alya Abd Alaziz Najim Al Zobair
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
